Roth Capital Resumes Coverage on Halozyme Therapeutics (HALO) at Buy
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $104.89 +1.83%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Roth Capital resumes coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy. PT $14.00.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.02 yesterday.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Halozyme Appoints Dannielle Appelhans to its Board of Directors
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
